An FGFR 3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
An FGFR 3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers ; volume:10 ; number:4 ; year:2018 ; extent:18
EMBO molecular medicine / European Molecular Biology Organization ; 10, Heft 4 (2018) (gesamt 18)
- Creator
-
Mahe, Mélanie
Dufour, Florent
Neyret‐Kahn, Hélène
Moreno‐Vega, Aura
Beraud, Claire
Shi, Mingjun
Hamaidi, Imene
Sanchez‐Quiles, Virginia
Krucker, Clementine
Dorland‐Galliot, Marion
Chapeaublanc, Elodie
Nicolle, Remy
Lang, Hervé
Pouponnot, Celio
Massfelder, Thierry
Radvanyi, François
Bernard‐Pierrot, Isabelle
- DOI
-
10.15252/emmm.201708163
- URN
-
urn:nbn:de:101:1-2022091018500868566142
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mahe, Mélanie
- Dufour, Florent
- Neyret‐Kahn, Hélène
- Moreno‐Vega, Aura
- Beraud, Claire
- Shi, Mingjun
- Hamaidi, Imene
- Sanchez‐Quiles, Virginia
- Krucker, Clementine
- Dorland‐Galliot, Marion
- Chapeaublanc, Elodie
- Nicolle, Remy
- Lang, Hervé
- Pouponnot, Celio
- Massfelder, Thierry
- Radvanyi, François
- Bernard‐Pierrot, Isabelle
Other Objects (12)
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
What lies beneath: Hydra provides cnidarian perspectives into the evolution of FGFR docking proteins
Targeted Therapies in Low-Grade Serous Ovarian Cancers
Targeting FGFR for cancer therapy
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
New therapies for advanced, recurrent, and metastatic endometrial cancers
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies
Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
MYC amplification in subtypes of breast cancers in African American women
Emerging roles of Myc in stem cell biology and novel tumor therapies
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
What lies beneath: Hydra provides cnidarian perspectives into the evolution of FGFR docking proteins
Targeted Therapies in Low-Grade Serous Ovarian Cancers
Targeting FGFR for cancer therapy
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
New therapies for advanced, recurrent, and metastatic endometrial cancers
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies
Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
MYC amplification in subtypes of breast cancers in African American women
Emerging roles of Myc in stem cell biology and novel tumor therapies
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
What lies beneath: Hydra provides cnidarian perspectives into the evolution of FGFR docking proteins
Targeted Therapies in Low-Grade Serous Ovarian Cancers
Targeting FGFR for cancer therapy
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
New therapies for advanced, recurrent, and metastatic endometrial cancers
Novel targeted therapies and immunotherapy for advanced thyroid cancers
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies
Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
MYC amplification in subtypes of breast cancers in African American women